Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIRCERA vs OMONTYS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator that stimulates erythropoiesis by binding to and activating the erythropoietin receptor, leading to increased red blood cell production.
Erythropoiesis-stimulating agent; synthetic peptide agonist of the erythropoietin receptor (EPOR) that stimulates erythropoiesis in red blood cell precursors.
Treatment of anemia associated with chronic kidney disease in adult patients on dialysis and not on dialysis
Anemia due to chronic kidney disease (CKD) in adults on dialysis and not on dialysis
Initial dose 0.6 mcg/kg intravenously or subcutaneously every 2 weeks; for patients not on dialysis, initial dose 1.2 mcg/kg subcutaneously every 2 weeks; target hemoglobin 10-12 g/d L.
45 mg subcutaneously once every 4 weeks (monthly) in adults.
Terminal half-life approximately 130-140 hours (about 5-6 days) in patients with chronic kidney disease. This long half-life supports once-monthly dosing. In healthy volunteers, half-life is about 134 hours.
Terminal elimination half-life is approximately 14.5 hours in healthy adults; in hemodialysis patients, half-life is extended to 26.4–29.9 hours, supporting weekly dosing.
MIRCERA is primarily eliminated via the reticuloendothelial system and not metabolized by cytochrome P450 enzymes. Minor degradation occurs via proteolysis.
Not metabolized by cytochrome P450 enzymes; degraded into small peptides and amino acids via catabolic pathways.
Renal (minimal, as MIRCERA is a large glycoprotein that is not significantly filtered by the glomerulus). The majority is eliminated via binding to EPO receptors on target cells followed by internalization and degradation, with less than 10% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. The iron component is incorporated into hemoglobin or stored as ferritin/hemosiderin.
Approximately 50-60% bound to serum proteins, primarily albumin, though binding is reversible and not restrictive.
Ferric pyrophosphate citrate moiety: <5% bound to plasma proteins; iron is rapidly transferred to transferrin.
Approximately 3.3 L in a 70 kg patient (about 0.047 L/kg), indicating limited distribution primarily to plasma volume. This reflects the large molecular weight of the methoxy polyethylene glycol-epoetin beta conjugate, which restricts extravascular distribution.
Vd approximately 0.47 L/kg (range 0.2–0.8 L/kg), indicating distribution primarily into plasma and interstitial fluid; iron distributes to bone marrow and reticuloendothelial system.
Subcutaneous: Approximately 62% relative to intravenous administration. Peak serum concentration occurs 72-120 hours post-dose. Absolute bioavailability not determined due to the drug's endogenous comparators.
Not applicable; OMONTYS is administered only intravenously. Oral bioavailability is not relevant.
No dose adjustment required for GFR <30 m L/min; use with caution in patients with chronic kidney disease not on dialysis; monitor hemoglobin closely.
No dosage adjustment required for any degree of renal impairment, including end-stage renal disease.
No specific Child-Pugh based dosing; use with caution in severe hepatic impairment; no clinical data available.
No dosage adjustment recommended for mild or moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Not approved for pediatric patients; safety and efficacy not established.
Safety and efficacy in pediatric patients have not been established; no recommended dose.
No specific dose adjustment for elderly; initial dose based on body weight; monitor hemoglobin and iron status.
No specific dosage adjustment needed; consider age-related renal function and individual tolerability.
WARNING: ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence. To reduce these risks, use the lowest dose sufficient to avoid red blood cell transfusion. For patients with chronic kidney disease, use only when hemoglobin is <10 g/d L and individualize dosing to maintain hemoglobin between 10-12 g/d L. Not indicated for use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
Increased risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and mortality when targeting hemoglobin levels >11 g/d L; increased risk of tumor progression and recurrence in patients with cancer; not indicated for treatment of anemia in cancer patients due to increased risk of death and serious cardiovascular events.
Increased mortality and cardiovascular events,Increased risk of thrombotic events and vascular access thrombosis,Increased mortality in cancer patients not receiving myelosuppressive chemotherapy,Hypertension,Seizures,Pure red cell aplasia due to anti-erythropoietin antibodies,Serious allergic reactions including anaphylaxis,Tumor progression in cancer patients
Increased mortality, serious cardiovascular events, and thromboembolic events; hypertension; seizures; pure red cell aplasia (PRCA) with neutralizing antibodies; increased risk of tumor progression in cancer patients; hemoglobin monitoring; iron deficiency management; hypersensitivity reactions including anaphylaxis.
Uncontrolled hypertension,History of serious allergic reactions to MIRCERA or any of its components,Pure red cell aplasia after prior ESA therapy
Uncontrolled hypertension; history of pure red cell aplasia (PRCA) following erythropoiesis-stimulating agents; known hypersensitivity to OMONTYS or any of its components.
No significant food interactions. However, maintain adequate dietary iron intake as directed. Avoid excessive alcohol, which can affect erythropoiesis.
No clinically significant food interactions reported. Administer subcutaneously, independent of meals.
Pregnancy Category B. Animal studies show no evidence of fetal harm. No adequate human studies in first trimester. Use only if clearly needed. Potential increased risk of thrombotic events in pregnant women.
OMONTYS (pegcetacoplan) is a complement inhibitor. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed at maternal exposures up to 20 times the human exposure at the recommended clinical dose. Based on its mechanism of action as a complement inhibitor, there is a theoretical risk of increased susceptibility to infections for the fetus, but no specific teratogenic effects have been identified. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Unknown if excreted in human milk. Caution advised. M/P ratio not determined.
It is unknown whether pegcetacoplan is excreted in human milk, affects the breastfed infant, or affects milk production. No data on the milk-to-plasma (M/P) ratio are available. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pharmacokinetic changes in pregnancy may require dose adjustments; however, specific guidelines are lacking. Titrate dose to maintain hemoglobin within target range (typically 10-12 g/d L). Monitor closely for excessive erythropoiesis.
No specific pharmacokinetic studies have been conducted in pregnant women. Based on the drug's large molecular weight and subcutaneous route, significant alterations in clearance due to pregnancy-induced physiological changes (e.g., increased blood volume, renal clearance) are possible but not quantified. The recommended dose for non-pregnant adults is 1080 mg subcutaneously twice weekly. No formal dose adjustment is recommended during pregnancy due to lack of data; however, close monitoring for clinical efficacy and safety is advised. Dose adjustments should be guided by therapeutic response and tolerability.
MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator (CERA) with a long half-life (approx. 130 hours). Administer intravenously or subcutaneously once every two weeks or once monthly. Monitor hemoglobin weekly until stable, then every 2-4 weeks. Target hemoglobin 10-11 g/d L; do not exceed 12 g/d L to avoid cardiovascular and thromboembolic risks. Dose reductions recommended if HB rises >1 g/d L in 2 weeks. Iron stores must be repleted (transferrin saturation ≥20%, ferritin ≥100 ng/m L). Avoid in patients with uncontrolled hypertension.
OMONTYS (pegcetacoplan) is a C3 inhibitor approved for paroxysmal nocturnal hemoglobinuria (PNH). Initiate only in patients vaccinated against encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b) due to increased infection risk. Monitor for hemolysis, thrombosis, and breakthrough disease; consider dose adjustments if hemoglobin drops significantly. Do not discontinue abruptly—switch to alternative therapy under medical supervision.
This medication is given as an injection every 2 weeks or once a month to treat anemia due to chronic kidney disease.,Do not miss doses; if you do, contact your healthcare provider as soon as possible.,Report symptoms of high blood pressure (severe headache, blurred vision, chest pain), blood clots (pain, swelling, redness in legs; sudden shortness of breath), or allergic reactions (rash, itching, difficulty breathing).,Your hemoglobin will be monitored regularly; inform your doctor of any symptoms of anemia (fatigue, pale skin) or excess red blood cells (headache, dizziness).,Iron supplements may be needed; take them exactly as prescribed.
You must receive vaccinations against meningococcus, pneumococcus, and Haemophilus influenzae type b before starting OMONTYS and maintain up-to-date immunizations.,Report any signs of infection immediately: fever, headache with stiff neck, confusion, chills, or rash.,Do not stop taking OMONTYS without talking to your doctor—sudden discontinuation may cause serious hemolysis.,You may experience injection site reactions; rotate injection sites and avoid injecting into tender or scarred areas.,Store OMONTYS in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from light.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIRCERA vs OMONTYS, answered by our medical review team.
MIRCERA is a Erythropoiesis-Stimulating Agent that works by MIRCERA (methoxy polyethylene glycol-epoetin beta) is a continuous erythropoietin receptor activator that stimulates erythropoiesis by binding to and activating the erythropoietin receptor, leading to increased red blood cell production.. OMONTYS is a Erythropoiesis-Stimulating Agent that works by Erythropoiesis-stimulating agent; synthetic peptide agonist of the erythropoietin receptor (EPOR) that stimulates erythropoiesis in red blood cell precursors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIRCERA and OMONTYS depend on the specific clinical indication. These are both Erythropoiesis-Stimulating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIRCERA is: Initial dose 0.6 mcg/kg intravenously or subcutaneously every 2 weeks; for patients not on dialysis, initial dose 1.2 mcg/kg subcutaneously every 2 weeks; target hemoglobin 10-12 g/d L.. The standard adult dose of OMONTYS is: 45 mg subcutaneously once every 4 weeks (monthly) in adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIRCERA and OMONTYS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIRCERA is classified as Category C. Pregnancy Category B. Animal studies show no evidence of fetal harm. No adequate human studies in first trimester. Use only if clearly needed. Potential increased risk of thromboti. OMONTYS is classified as Category C. OMONTYS (pegcetacoplan) is a complement inhibitor. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental eff. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.